Grifols

Grifols's reported carbon emissions

Grifols, a pharmaceutical preparation manufacturing company headquartered in Spain, has reported its carbon emissions for recent years. In 2025, the company's total emissions were approximately 1.36 billion kg CO2e. This figure comprises Scope 1 emissions of about 121.9 million kg CO2e, and Scope 2 emissions (market-based) of approximately 83.9 million kg CO2e. Scope 3 emissions accounted for the largest portion, totalling about 1.15 billion kg CO2e. Key contributors to Scope 3 emissions include purchased goods and services (around 554.2 million kg CO2e) and upstream transportation and distribution (approximately 317.9 million kg CO2e). In 2024, Grifols reported total emissions of approximately 1.23 billion kg CO2e, with Scope 1 at about 123.2 million kg CO2e, Scope 2 (market-based) at around 166.1 million kg CO2e, and Scope 3 at approximately 1.12 billion kg CO2e. For 2023, total emissions were reported at approximately 1.15 billion kg CO2e, with Scope 1 at about 124.8 million kg CO2e, Scope 2 (market-based) at approximately 98.1 million kg CO2e, and Scope 3 at around 998.3 million kg CO2e. Grifols has established several climate commitments and reduction targets. The company aims to achieve net-zero emissions by 2050 for Scopes 1 and 2. More immediately, Grifols has committed to reducing absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 42% by 2030, using 2022 as the baseline year. Furthermore, the company is targeting a 25% reduction in absolute Scope 3 GHG emissions by 2030, focusing on categories such as purchased goods and services, capital goods, fuel- and energy-related activities, and upstream transportation and distribution, also from a 2022 baseline. Grifols also aims to reduce GHG emissions per unit of production by 55% by 2030, compared to 2018 levels. Some reports also indicate an ambition to reduce Scope 1 and Scope 2 emissions to near zero by the middle of the current decade.